K Gelmon

Summary

Affiliation: British Columbia
Country: Canada

Publications

  1. ncbi The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer
    Stephen K Chia
    Division of Medical Oncology, British Columbia Cancer Agency and the University of British Columbia, Vancouver and Victoria, British Columbia, Canada
    Cancer 110:973-9. 2007
  2. ncbi Effect of soy phytoestrogens on hot flashes in postmenopausal women with breast cancer: a randomized, controlled clinical trial
    Cheri L Van Patten
    British Columbia Cancer Agency, Vancouver Cancer Centre, Vancouver Hospital and Health Sciences Centre, and University of British Columbia, Vancouver, British Columbia, Canada
    J Clin Oncol 20:1449-55. 2002
  3. ncbi Targeting triple-negative breast cancer: optimising therapeutic outcomes
    K Gelmon
    Department of Medicine, University of British Columbia, Vancouver, Canada
    Ann Oncol 23:2223-34. 2012
  4. ncbi Understanding breast cancer patients' preference for two types of exercise training during chemotherapy in an unblinded randomized controlled trial
    Kerry S Courneya
    Faculty of Physical Education and Recreation, University of Alberta, Edmonton, Alberta, Canada
    Int J Behav Nutr Phys Act 5:52. 2008
  5. ncbi The ability of cancer-specific and generic preference-based instruments to discriminate across clinical and self-reported measures of cancer severities
    Paulos Teckle
    Canadian Centre for Applied Research in Cancer Control ARCC, Vancouver, BC, Canada
    Health Qual Life Outcomes 9:106. 2011
  6. ncbi Can clinically relevant prognostic subsets of breast cancer patients with four or more involved axillary lymph nodes be identified through immunohistochemical biomarkers? A tissue microarray feasibility study
    Simon J Crabb
    Department of Medical Oncology, BC Cancer Agency, 600 West 10th Avenue, Vancouver, BC, Canada, V5Z 4E6
    Breast Cancer Res 10:R6. 2008
  7. ncbi Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes
    Golareh Habibi
    Laboratory for Oncogenomic Research, Departments of Pediatrics and Experimental Medicine, Child and Family Research Institute, University of British Columbia, Vancouver, Canada
    Breast Cancer Res 10:R86. 2008
  8. ncbi QLT0267, a small molecule inhibitor targeting integrin-linked kinase (ILK), and docetaxel can combine to produce synergistic interactions linked to enhanced cytotoxicity, reductions in P-AKT levels, altered F-actin architecture and improved treatment outc
    Jessica Kalra
    Advanced Therapeutics, BC Cancer Agency, Vancouver, British Columbia, Canada
    Breast Cancer Res 11:R25. 2009
  9. ncbi The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity
    Wieslawa H Dragowska
    Experimental Therapeutics, British Columbia Cancer Agency, 675 West 10th Ave, Vancouver, BC V5Z 1L3, Canada
    BMC Cancer 11:420. 2011
  10. ncbi Part II: Milestones in personalised medicine--trastuzumab
    Karen Gelmon
    BC Cancer Agency, University of British Columbia, Vancouver, BC, Canada
    Lancet Oncol 9:698. 2008

Detail Information

Publications60

  1. ncbi The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer
    Stephen K Chia
    Division of Medical Oncology, British Columbia Cancer Agency and the University of British Columbia, Vancouver and Victoria, British Columbia, Canada
    Cancer 110:973-9. 2007
    ..This study characterized the use and assessed the impact on survival of population-based access to new agents for the treatment of MBC...
  2. ncbi Effect of soy phytoestrogens on hot flashes in postmenopausal women with breast cancer: a randomized, controlled clinical trial
    Cheri L Van Patten
    British Columbia Cancer Agency, Vancouver Cancer Centre, Vancouver Hospital and Health Sciences Centre, and University of British Columbia, Vancouver, British Columbia, Canada
    J Clin Oncol 20:1449-55. 2002
    ..This study evaluated the acceptability and effectiveness of a soy beverage containing phytoestrogens as a treatment for hot flashes in postmenopausal women with breast cancer...
  3. ncbi Targeting triple-negative breast cancer: optimising therapeutic outcomes
    K Gelmon
    Department of Medicine, University of British Columbia, Vancouver, Canada
    Ann Oncol 23:2223-34. 2012
    ..It is highly heterogeneous and displays overlapping characteristics with both basal-like and BC susceptibility gene 1 and 2 mutant BCs. This review evaluates the activity of emerging targeted agents in TNBC...
  4. ncbi Understanding breast cancer patients' preference for two types of exercise training during chemotherapy in an unblinded randomized controlled trial
    Kerry S Courneya
    Faculty of Physical Education and Recreation, University of Alberta, Edmonton, Alberta, Canada
    Int J Behav Nutr Phys Act 5:52. 2008
    ..The purpose of the present study was to examine factors associated with breast cancer patients' preference for two types of exercise training during chemotherapy...
  5. ncbi The ability of cancer-specific and generic preference-based instruments to discriminate across clinical and self-reported measures of cancer severities
    Paulos Teckle
    Canadian Centre for Applied Research in Cancer Control ARCC, Vancouver, BC, Canada
    Health Qual Life Outcomes 9:106. 2011
    ..To evaluate the validity of cancer-specific and generic preference-based instruments to discriminate across different measures of cancer severities...
  6. ncbi Can clinically relevant prognostic subsets of breast cancer patients with four or more involved axillary lymph nodes be identified through immunohistochemical biomarkers? A tissue microarray feasibility study
    Simon J Crabb
    Department of Medical Oncology, BC Cancer Agency, 600 West 10th Avenue, Vancouver, BC, Canada, V5Z 4E6
    Breast Cancer Res 10:R6. 2008
    ..Primary breast cancer involving four or more axillary lymph nodes carries a poor prognosis. We hypothesized that use of an immunohistochemical biomarker scoring system could allow for identification of variable risk subgroups...
  7. ncbi Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes
    Golareh Habibi
    Laboratory for Oncogenomic Research, Departments of Pediatrics and Experimental Medicine, Child and Family Research Institute, University of British Columbia, Vancouver, Canada
    Breast Cancer Res 10:R86. 2008
    ..We therefore investigated whether YB-1 identifies patients at risk for either reduced relapse free survival or decreased r breast cancer specific survival (BCSS) across all tumor subtypes by evaluating 4,049 cases...
  8. ncbi QLT0267, a small molecule inhibitor targeting integrin-linked kinase (ILK), and docetaxel can combine to produce synergistic interactions linked to enhanced cytotoxicity, reductions in P-AKT levels, altered F-actin architecture and improved treatment outc
    Jessica Kalra
    Advanced Therapeutics, BC Cancer Agency, Vancouver, British Columbia, Canada
    Breast Cancer Res 11:R25. 2009
    ..The purpose of this study was to investigate the therapeutic potential of the ILK small molecule inhibitor, QLT0267 (267), alone or in combination with chemotherapies commonly used to treat breast cancer patients...
  9. ncbi The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity
    Wieslawa H Dragowska
    Experimental Therapeutics, British Columbia Cancer Agency, 675 West 10th Ave, Vancouver, BC V5Z 1L3, Canada
    BMC Cancer 11:420. 2011
    ..Here, we assessed feasibility of combining the EGFR inhibitor gefitinib and the mTOR inhibitor everolimus (RAD001) for treating HER2 overexpressing breast cancers with different sensitivity to TZ...
  10. ncbi Part II: Milestones in personalised medicine--trastuzumab
    Karen Gelmon
    BC Cancer Agency, University of British Columbia, Vancouver, BC, Canada
    Lancet Oncol 9:698. 2008
  11. ncbi Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
    Karen A Gelmon
    BC Cancer Agency, Vancouver, Canada
    Lancet Oncol 12:852-61. 2011
    ..We aimed to assess the safety and tolerability of this drug in patients without BRCA1 or BRCA2 mutations with advanced triple-negative breast cancer or high-grade serous and/or undifferentiated ovarian cancer...
  12. ncbi Prescribing extended adjuvant letrozole
    K Gelmon
    BC Cancer Research Centre, 675 West 10th Avenue, Vancouver, BC Canada V5Z 1L3
    Breast 16:446-55. 2007
    ....
  13. ncbi A phase II study of ZD0473 given as a short infusion every 3 weeks to patients with advanced or metastatic breast cancer: a National Cancer Institute of Canada Clinical Trials Group trial, IND 129
    K A Gelmon
    British Columbia Cancer Agency Vancouver Cancer Center, Canada
    Ann Oncol 14:543-8. 2003
    ..A phase II study of ZD0473 in advanced breast cancer was initiated by the National Cancer Institute of Canada Clinical Trials Group...
  14. ncbi A phase I study of T900607 given once every 3 weeks in patients with advanced refractory cancers; National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) IND 130
    Karen A Gelmon
    British Columbia Cancer Agency, Vancouver Cancer Centre, Vancouver, BC, Canada, V5Z 4E6
    Invest New Drugs 23:445-53. 2005
    ..This phase I trial was conducted to determine the maximum tolerated dose, recommended phase II dose, pharmacokinetic properties and toxicities of this agent...
  15. ncbi The 2000 EBCTCG overview: a widening gap
    S Chia
    British Columbia Cancer Agency, Vancouver, BC V5Z 4E6, Canada
    Lancet 365:1665-6. 2005
  16. ncbi A phase I study of AMD473 and docetaxel given once every 3 weeks in patients with advanced refractory cancer: a National Cancer Institute of Canada-Clinical Trials Group trial, IND 131
    K A Gelmon
    British Columbia Cancer Agency, Vancouver Cancer Centre, Vancouver, BC
    Ann Oncol 15:1115-22. 2004
    ..To assess its potential combined with a taxane, a phase I study of AMD473 and docetaxel in advanced cancer was initiated by the National Cancer Institute of Canada-Clinical Trials Group...
  17. ncbi A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers
    K Gelmon
    British Columbia Cancer Agency, Vancouver Cancer Centre, Vancouver, BC, Canada
    Invest New Drugs 22:263-75. 2004
    ....
  18. ncbi The mammography screening debate: time to move on
    Karen A Gelmon
    British Columbia Cancer Agency-Vancouver Cancer Centre, BC, V5Z 4E6, Vancouver, Canada
    Lancet 359:904-5. 2002
  19. ncbi Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories
    Karen A Gelmon
    British Columbia Cancer Agency, Vancouver, Canada
    Clin Breast Cancer 5:52-8; discussion 59-62. 2004
    ..The feasibility of this approach warrants examination in prospective trials...
  20. ncbi Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer
    K Gelmon
    British Columbia Cancer Agency, Vancouver, Canada
    J Clin Oncol 17:3038-47. 1999
    ..Secondary objectives included comparing myelosuppression, myalgias, and response rates of the two groups...
  21. ncbi Phase I study of liposomal vincristine
    K A Gelmon
    British Columbia Cancer Agency, Vancouver, Canada
    J Clin Oncol 17:697-705. 1999
    ..The primary objectives were to determine the maximum-tolerated dose (MTD), recommended phase II dose, toxicity, and pharmacokinetics of liposomal vincristine (ONCO-TCS)...
  22. ncbi Phase I dose-finding study of a new taxane, RPR 109881A, administered as a one-hour intravenous infusion days 1 and 8 to patients with advanced solid tumors
    K A Gelmon
    British Columbia Cancer Agency, Vancouver Cancer Centre, Vancouver, British Columbia, Canada
    J Clin Oncol 18:4098-108. 2000
    ..To define the maximum-tolerated dose, recommended phase II dose (RD), dose-limiting toxicity (DLT), and pharmacokinetics of a novel taxane, RPR 109881A, administered on days 1 and 8 of a 21-day cycle...
  23. ncbi Lapatinib for breast cancer: a review of the current literature
    Robyn J Macfarlane
    British Columbia Cancer Agency Medical Oncology, 600 West 10th Avenue, Vancouver, BC, Canada
    Expert Opin Drug Saf 10:109-21. 2011
    ..Lapatinib is an oral tyrosine kinase inhibitor which has both HER-1 and -2 activities and has been licensed for use in recurrent breast cancer that overexpresses HER-2. Studies of lapatinib in early breast cancer are ongoing...
  24. ncbi Molecular predictive factors in patients receiving trastuzumab-based chemotherapy for metastatic disease
    Andrew G Robinson
    Division of Medical Oncology, BC Cancer Agency, Canada
    Clin Breast Cancer 7:254-61. 2006
    ..In addition to HER2 expression, other molecular markers are needed to better predict outcomes after the initiation of trastuzumab-based chemotherapy and to elucidate potential mechanisms of resistance to trastuzumab...
  25. ncbi Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer
    J M Nabholtz
    Cross Cancer Institute, Department of Medicine, Edmonton, Alberta, Canada
    J Clin Oncol 14:1858-67. 1996
    ..A total of 471 patients with MBC were randomized to receive intravenous paclitaxel at a dose of 175 or 135 mg/m2 every 3 weeks...
  26. ncbi Abbreviated treatment for elderly, infirm, or noncompliant patients with limited-stage small-cell lung cancer
    N Murray
    Lung Tumor Group, Vancouver Center, British Columbia Cancer Agency, Canada
    J Clin Oncol 16:3323-8. 1998
    ....
  27. ncbi Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival
    Sam M Wiseman
    Genetic Pathology Evaluation Center at the Prostate Research Center of Vancouver General Hospital and British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    Cancer 103:1770-7. 2005
    ..The objective of the current study was to determine the frequency and the possible prognostic effect of coexpression of HER-1, HER-2, HER-3, and HER-4 by breast carcinoma...
  28. ncbi The presence of stromal mast cells identifies a subset of invasive breast cancers with a favorable prognosis
    Shahriar Dabiri
    Department of Pathology, British Columbia Cancer Agency, Vancouver, BC, Canada
    Mod Pathol 17:690-5. 2004
    ....
  29. ncbi Decline in pulmonary function in patients with breast cancer receiving dose-dense chemotherapy: a prospective study
    R Yerushalmi
    Institute of Oncology, Davidoff Center, Beilinson Campus, Petah Tiqva and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    Ann Oncol 20:437-40. 2009
    ..Prompted by complaints of dyspnea in breast cancer patients receiving adjuvant dose-dense chemotherapy (DDC), we sought to evaluate the possible association of DDC with pulmonary dysfunction...
  30. ncbi Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers
    Stephen Chia
    Division of Medical Oncology, Breast Cancer Outcomes Unit, British Columbia Cancer Agency, University of British Columbia, Vancouver, British Columbia, Canada
    J Clin Oncol 26:5697-704. 2008
    ..This study assessed the prognostic impact of HER2 overexpression/amplification in a large series of node-negative breast cancers...
  31. ncbi Phase II trial of OGX-011 in combination with docetaxel in metastatic breast cancer
    Stephen Chia
    Division of Medical Oncology, British Columbia Cancer Agency, University of British Columbia, 600 West 10th Avenue, Vancouver, British Columbia, Canada V5Z 4E6
    Clin Cancer Res 15:708-13. 2009
    ..The primary objective of this phase II trial was to assess the safety and efficacy of the combination of OGX-011 and docetaxel for metastatic breast cancer...
  32. ncbi Patterns of relapse in breast cancer: changes over time
    Rinat Yerushalmi
    Division of Medical Oncology, British Columbia Cancer Agency, University of British Columbia, Vancouver, BC, V5Z 4E6, Canada
    Breast Cancer Res Treat 120:753-9. 2010
    ..Understanding patterns of relapse may help design new adjuvant strategies...
  33. ncbi Is Canadian women's breast cancer screening behaviour associated with having a family doctor?
    Barbara Poole
    Cancer Control Research, BC Cancer Agency, 675 W 10th Ave, 2nd Floor, Suite 115, Vancouver, BC V5Z 1L3
    Can Fam Physician 56:e150-7. 2010
    ..To assess whether regular care from a family physician is associated with regular participation in screening mammography...
  34. ncbi Breast cancer subtypes and the risk of local and regional relapse
    K David Voduc
    Department of Radiation Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada V5Z 4E6
    J Clin Oncol 28:1684-91. 2010
    ..Subtype assignment was accomplished using a validated six-marker immunohistochemical panel applied to tissue microarrays...
  35. ncbi Metastatic behavior of breast cancer subtypes
    Hagen Kennecke
    Vancouver Clinic, Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    J Clin Oncol 28:3271-7. 2010
    ..Prognostic and predictive factors are well established in early-stage breast cancer, but less is known about which metastatic sites will be affected...
  36. ncbi Decreased levels of hypoxic cells in gefitinib treated ER+ HER-2 overexpressing MCF-7 breast cancer tumors are associated with hyperactivation of the mTOR pathway: therapeutic implications for combination therapy with rapamycin
    Wieslawa H Dragowska
    Department of Advanced Therapeutics, British Columbia Cancer Agency, 675 West 10th Ave, Vancouver, BC, Canada, V5Z 1L3
    Breast Cancer Res Treat 106:319-31. 2007
    ..Chou and Talalay analysis of the data suggested that combination of gefitinib and rapamycin was synergistic (CI < 1) at a number of selected drug ratios and over a broad range of effective doses...
  37. ncbi Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-stage breast cancer
    Caroline Lohrisch
    Breast Cancer Outcomes Unit, British Columbia Cancer Agency, Vancouver
    J Clin Oncol 24:4888-94. 2006
    ..To determine if time to start of adjuvant chemotherapy after curative surgery influences survival in early-stage breast cancer...
  38. ncbi Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial
    Stephen Chia
    British Columbia Cancer Agency, Vancouver Cancer Centre, Vancouver, BC, Canada
    J Clin Oncol 24:2773-8. 2006
    ....
  39. ncbi Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fraction
    Corinna Warburton
    Department of Advanced Therapeutics, British Columbia Cancer Agency, Vancouver, Canada
    Clin Cancer Res 10:2512-24. 2004
    ....
  40. ncbi HER-2/neu overexpression increases the viable hypoxic cell population within solid tumors without causing changes in tumor vascularization
    Wieslawa H Dragowska
    Department of Advanced Therapeutics, British Columbia Cancer Agency, 600 West 10th Avenue, Vancouver, British Columbia, Canada V5Z 4E6
    Mol Cancer Res 2:606-19. 2004
    ..These results suggest that HER-2/neu overexpression may be linked with overall increased tumor viability and a significant increase in the population of viable hypoxic cells, which is not due to differences in tumor vascularization...
  41. ncbi Chemotherapy for oestrogen-receptor-negative breast cancer
    Rinat Yerushalmi
    British Columbia Cancer Agency, Vancouver, BC, Canada V5Z 4E6
    Lancet 371:4-5. 2008
  42. ncbi The role of capecitabine in first-line treatment for patients with metastatic breast cancer
    Karen Gelmon
    British Columbia Cancer Agency, Vancouver, Canada
    Oncologist 11:42-51. 2006
    ..Recently, clinical trials have studied single-agent capecitabine as first-line treatment and evaluated other capecitabine-containing combinations with cytotoxic and novel targeted agents...
  43. ncbi Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution
    Sohrab P Shah
    Molecular Oncology, BC Cancer Agency, 675 West 10th Avenue, Vancouver V5Z 1L3, Canada
    Nature 461:809-13. 2009
    ..Taken together, our data show that single nucleotide mutational heterogeneity can be a property of low or intermediate grade primary breast cancers and that significant evolution can occur with disease progression...
  44. ncbi Analytical and preanalytical biases in serum proteomic pattern analysis for breast cancer diagnosis
    Aly Karsan
    Department of Pathology and Laboratory Medicine, British Columbia Cancer Agency, Vancouver, BC, Canada
    Clin Chem 51:1525-8. 2005
  45. ncbi Trastuzumab and liposomal Doxorubicin in the treatment of mcf-7 xenograft tumor-bearing mice: combination does not affect drug serum levels
    Dawn N Waterhouse
    BC Cancer Agency, USA
    Pharm Res 22:915-22. 2005
    ....
  46. ncbi Trastuzumab-associated peripheral vascular toxicity
    Gary K Pansegrau
    British Columbia Cancer Agency, Fraser Valley Centre, Surrey, British Columbia, Canada
    J Clin Oncol 25:1438-40. 2007
  47. ncbi Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival
    Maggie C U Cheang
    Genetic Pathology Evaluation Centre at Vancouver General Hospital, Prostate Centre, and University of British Columbia, Vancouver, British Columbia, Canada
    J Clin Oncol 24:5637-44. 2006
    ..CONCLUSION: SP1 represents an improved standard for ER immunohistochemistry assessment in breast cancer...
  48. ncbi Population-based validation of the prognostic model ADJUVANT! for early breast cancer
    Ivo A Olivotto
    Breast Cancer Outcomes Unit, Vancouver Island Centre, 2410 Lee Avenue, Victoria, BC V8R 6V5, Canada
    J Clin Oncol 23:2716-25. 2005
    ..Adjuvant! (www.adjuvantonline.com) is a web-based tool that predicts 10-year breast cancer outcomes with and without adjuvant systemic therapy, but it has not been independently validated...
  49. ncbi Lymph-node-negative oestrogen-receptor-positive breast cancer
    Gary K Pansegrau
    British Columbia Cancer Agency, Vancouver, British Columbia, Canada V5Z 4E6
    Lancet 364:820-1. 2004
  50. ncbi A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer
    Kim N Chi
    BC Cancer Agency, Vancouver, British Columbia, Canada
    Invest New Drugs 23:311-5. 2005
    ..Phase I trials of ONT-093 in normal human volunteers showed no dose-limiting toxicities at serum concentrations associated with biologic activity achieved with doses ranging from 300 to 500 mg...
  51. ncbi MDM2 protein expression is a negative prognostic marker in breast carcinoma
    Dmitry A Turbin
    Genetic Pathology Evaluation Centre of the Department of Pathology, British Columbia Cancer Agency and University of British Columbia, Vancouver, BC, Canada
    Mod Pathol 19:69-74. 2006
    ..Immunohistochemical studies of MDM2 in more than 2000 breast carcinomas show that MDM2 is an independent negative prognostic marker...
  52. ncbi Overexpression of the anti-adhesin podocalyxin is an independent predictor of breast cancer progression
    Aruna Somasiri
    Department of Anatomy and Cell Biology, University of British Columbia, 2177 Wesbrook Mall, Vancouver, BC, Canada V6T 1Z3
    Cancer Res 64:5068-73. 2004
    ..Therefore, podocalyxin overexpression is a novel predictor of breast cancer progression that may contribute to the process by perturbing tumor cell adhesion...
  53. ncbi Combining doxorubicin and liposomal anti-HER-2/NEU antisense oligodeoxynucleotides to treat HER-2/NEU-expressing MDA-MB-435 breast tumor model
    Dawn N Waterhouse
    British Columbia Cancer Research Centre, Department of Advanced Therapeutics, Vancouver, Canada
    J Exp Ther Oncol 3:261-71. 2003
    ....
  54. ncbi Phase I and pharmacologic study of the human DNA methyltransferase antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeks
    Alison J Davis
    National Cancer Institute, Canada
    Invest New Drugs 21:85-97. 2003
    ..Pharmacodynamic evaluations undertaken in an attempt to explore and validate the biological mechanisms of MG98 did not show dose-related effects...
  55. ncbi Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial
    Edith A Perez
    Division of Hematology Oncology, Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL 32224, USA
    J Clin Oncol 26:1231-8. 2008
    ..To assess cardiac safety and potential cardiac risk factors associated with trastuzumab in the NCCTG N9831 Intergroup adjuvant breast cancer trial...
  56. ncbi Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen
    Hagen Kennecke
    Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    Cancer 112:1437-44. 2008
    ..An understanding of which patients are at risk of early recurrence while they are receiving tamoxifen may improve clinical decision making...
  57. ncbi Facilitated "fast track" referral reduces time from abnormal screening mammogram to diagnosis
    Marilyn J Borugian
    Screening Mammography Program of British Columbia, British Columbia Cancer Agency, Vancouver, BC
    Can J Public Health 99:252-6. 2008
    ..The purpose of this study was to compare time intervals for patients evaluated through the Fast Track process with patients who were not...
  58. ncbi Identification of cancer care and protocol characteristics associated with recruitment in breast cancer clinical trials
    Julie Lemieux
    Unité de recherche en santé des populations, Centre des Maladies du Sein Deschênes Fabia, Hôpital St Sacrement, Quebec, Canada
    J Clin Oncol 26:4458-65. 2008
    ..Barriers to participation may relate to available protocols, physicians, and patients, but few data exist on barriers related to cancer care environments and protocol characteristics...
  59. ncbi Pharmacodynamic behavior of liposomal antisense oligonucleotides targeting Her-2/neu and vascular endothelial growth factor in an ascitic MDA435/LCC6 human breast cancer model
    Dawn N Waterhouse
    British Columbia Cancer Research Centre, Department of Advanced Therapeutics, Vancouver, BC, Canada
    Cancer Biol Ther 3:197-204. 2004
    ..Tissue distribution studies of both free and liposome encapsulated ASO indicated that ASO distribution was dictated primarily by the liposomal carrier when administered in liposomal form...
  60. ncbi Preferential dependence of breast cancer cells versus normal cells on integrin-linked kinase for protein kinase B/Akt activation and cell survival
    Armelle A Troussard
    Department of Cancer Genetics, British Columbia Cancer Research Centre, Vancouver, Canada
    Cancer Res 66:393-403. 2006
    ....